Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MIRO Miromatrix Medical (MIRO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Miromatrix Medical Stock (NASDAQ:MIRO) 30 days 90 days 365 days Advanced Chart Ad Stansberry ResearchThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" Click here to see Dan's new, urgent warning about the U.S. market for 2025. Get Miromatrix Medical alerts:Sign Up Key Stats Today's Range$3.39▼$3.3950-Day Range$3.31▼$3.4052-Week Range$0.91▼$4.35VolumeN/AAverage Volume80,095 shsMarket Capitalization$92.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMiromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.Read More… Receive MIRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Miromatrix Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address MIRO Stock News HeadlinesUniversity of Minnesota Venture Center Director Russ Straate retiresOctober 16, 2024 | bizjournals.comBioLargo, Inc.: Clyra Medical Technologies, a Subsidiary of BioLargo, Appoints Dr. Steven J. Kavros as Chief Medical OfficerSeptember 9, 2024 | finanznachrichten.deThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" December 22, 2024 | Stansberry Research (Ad)Clyra Medical Technologies Appoints Dr. Steven J. Kavros as Chief Medical OfficerSeptember 9, 2024 | finance.yahoo.comUnited Therapeutics to build $100M pig-to-human organ research center in southeast MinnesotaAugust 15, 2024 | startribune.comQ4 2023 United Therapeutics Corp Earnings CallFebruary 22, 2024 | uk.finance.yahoo.comBest Stocks to Buy Right NowNovember 22, 2023 | benzinga.comMiromatrix Medical GAAP EPS of -$0.24, revenue of $11.17MNovember 15, 2023 | msn.comSee More Headlines MIRO Stock Analysis - Frequently Asked Questions How were Miromatrix Medical's earnings last quarter? Miromatrix Medical Inc. (NASDAQ:MIRO) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.12. The company earned $0.01 million during the quarter. Miromatrix Medical had a negative net margin of 2,861.17% and a negative trailing twelve-month return on equity of 120.49%. When did Miromatrix Medical IPO? Miromatrix Medical (MIRO) raised $32 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 4,000,000 shares at a price of $7.00-$9.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. What other stocks do shareholders of Miromatrix Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Miromatrix Medical investors own include BitNile Metaverse (BNMV), Cognition Therapeutics (CGTX), Impel Pharmaceuticals (IMPL), Nyxoah (NYXH), Aceragen (ACGN), AcelRx Pharmaceuticals (ACRX) and Aldeyra Therapeutics (ALDX). Company Calendar Last Earnings11/15/2021Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MIRO CUSIPN/A CIK1527096 Webwww.miromatrix.com Phone952-942-6000FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,960,000.00 Net Margins-2,861.17% Pretax Margin-2,861.17% Return on Equity-120.49% Return on Assets-90.70% Debt Debt-to-Equity Ratio0.02 Current Ratio3.46 Quick Ratio3.46 Sales & Book Value Annual Sales$958,029.00 Price / Sales97.02 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book2.71Miscellaneous Outstanding Shares27,419,000Free Float25,993,000Market Cap$92.95 million OptionableOptionable Beta0.01 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:MIRO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miromatrix Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miromatrix Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.